Assay Cascade Design Sprint
We write an assay cascade for one program, from biochemical to translational readouts. It specifies which readout informs each decision, the threshold for that decision, and the order in which the assays run.
Decision it supports. Which assays to run, in what order, and which results move the program forward.
- For
-
A seed to Series B program that has a hit or a lead series and no one responsible for in vitro strategy.
- Scope
-
One program and one modality. A second modality is quoted as a change to the proposal. The three most common versions are glia and neuroimmune readouts, seeding and proteopathy models, and neuronal network assays for oligonucleotide and gene-targeted programs.
- Inputs
-
The target and mechanism hypotheses, the stage of the program, the budget, the assays already in use and the data they have produced.
- Deliverable
-
The Cascade Design Dossier, 15 to 30 pages, which contains:
- a cascade map from biochemical to cellular to functional to translational readouts
- a specification for each assay: system, plate format, readout, controls, quality gates, throughput and cost per plate
- a recommendation to build or outsource each assay
- a 90-day build plan with the critical path marked
- go/no-go criteria at every tier
- a fit-for-purpose validation section, informed by FDA's 2025 roadmap on new approach methodologies
- a one-page executive summary suitable for a board presentation
- Timeline
-
Two to three weeks, with a kickoff, one working session and a readout call.
- Excluded
-
We do not run experiments. Thalamus has no wet lab by choice, so the client's own bench or its CRO carries out the work.
Neuronal functionNeurodegeneration and proteinopathyNeuroimmunology and gliaImmunology and translational
Book a 30-minute call You answer a few short questions and choose a time. On the call we discuss your work and the decision you need to make.